177 related articles for article (PubMed ID: 34921596)
21. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
22. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
[TBL] [Abstract][Full Text] [Related]
23. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
[No Abstract] [Full Text] [Related]
24. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience.
Chen KA; Widger J; Teng A; Fitzgerald DA; D'Silva A; Farrar M
Paediatr Respir Rev; 2021 Sep; 39():54-60. PubMed ID: 33129670
[TBL] [Abstract][Full Text] [Related]
25. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
26. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
[TBL] [Abstract][Full Text] [Related]
27. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
[TBL] [Abstract][Full Text] [Related]
28. Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance.
Tachibana Y; Takasaki S; Hoshino M; Makioka H; Jin M
Int J Neurosci; 2024 Jun; 134(2):153-162. PubMed ID: 35787224
[No Abstract] [Full Text] [Related]
29. Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3.
Fainmesser Y; Drory VE; Ben-Shushan S; Lavon A; Spector L; Abramovich B; Abraham A
Neuromuscul Disord; 2022 Jun; 32(6):451-459. PubMed ID: 35527201
[TBL] [Abstract][Full Text] [Related]
30. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
[TBL] [Abstract][Full Text] [Related]
31. Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion.
Labianca L; Weinstein SL
J Pediatr Orthop B; 2019 Jul; 28(4):393-396. PubMed ID: 30932967
[TBL] [Abstract][Full Text] [Related]
32. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
33. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
[TBL] [Abstract][Full Text] [Related]
34. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy.
Nagarajan EK; Özütemiz C; Rubin N; Nascene DR
Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
[TBL] [Abstract][Full Text] [Related]
37. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study.
van der Heul AMB; Cuppen I; Wadman RI; Asselman F; Schoenmakers MAGC; van de Woude DR; Gerrits E; van der Pol WL; van den Engel-Hoek L
J Neuromuscul Dis; 2020; 7(3):323-330. PubMed ID: 32333596
[TBL] [Abstract][Full Text] [Related]
38. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
Bielsky AR; Fuhr PG; Parsons JA; Yaster M
Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
[TBL] [Abstract][Full Text] [Related]
39. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
[TBL] [Abstract][Full Text] [Related]
40. Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era.
Al Amrani F; Amin R; Chiang J; Xiao L; Boyd J; Law E; Nigro E; Weinstock L; Stosic A; Gonorazky HD
Neurol Clin Pract; 2022 Aug; 12(4):279-287. PubMed ID: 36382115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]